Jump to page content Accessibility
News, views and contacts from the global Drugdevelopment industry
Login to drugdevelopment-technology.com Log in or Register
  • Home
  • Products & Services
  • Company A - Z
  • Projects
  • Features
  • Videos
  • White Papers
  • News
  • Events
  • Advertise With Us
Industry Projects | Projects by Region | Projects by Category | Archived Projects | Project Gallery
 

Enbrel – Immunosuppressant for Treatment of Rheumatoid Arthritis



RA normally develops between the ages of 25 and 50 and affects more women than men.


  • Enbrel was the first biologic medicine approved for the treatment of moderate...

  • In those suffering from RA, TNF is produced in excess leading to chronic...

  • RA normally develops between the ages of 25 and 50 and affects more women...

Back to Project Details



Related Projects

Naproxcinod (HCT 3012) - COX-Inhibiting Nitric Oxide-Donator
Developed by French pharmaceutical company NicOx, naproxcinod (HCT 3012)...

Capravirine - Anti-Retroviral Drug
Developed by Pfizer Global Research and Development, capravirine is...

Lyrica (Pregabalin) - New Gabapentinoid with Wide
Developed by Pfizer, pregabalin, marketed under the brand name Lyrica, is...

Xolair - Biological Therapy
The product of a joint development programme between Tanox, Genentech...

Acomplia (Rimonabant) - Investigational Agent for
Developed by Sanofi-Aventis, Acomplia (rimonabant) is a selective...

See all projects


Contact us
Advertise with us
Terms and conditions
Privacy
Links
Newsletter sign up
Online magazine sign up

drugdevelopment-technology.com is a product of Net Resources International. Copyright 2011 Net Resources International, a trading division of SPG Media Limited.